Paclitaxel is widely used in the combination chemotherapy for many cancers including esophageal squamous cell carcinoma (ESCC). However, the paclitaxel resistance occurs frequently in treating ESCC and the mechanism is not fully understood yet. The heterogeneity of gene expression within the drug-resistant cancer cells may be one of the major factors contributing to its resistance. In the present study, we successfully induced paclitaxel resistance in ESCC cell line KYSE-30 through low dose and long-term treatment of paclitaxel.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2DY27RH
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Abstract Purpose To test the effects of 4 weeks of unilateral low-load resistance training (LLRT), with and without blood flow restricti...
-
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2juls25 via IFTTT
-
Swedish medical imaging software developer SyntheticMR has received the CE... Read more on AuntMinnieEurope.com Related Reading: Siemen...
-
A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor British Journal of Canc...
-
ACS Nano DOI: 10.1021/acsnano.6b06114 from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2kOsUGq via...
-
Long-term clinical outcomes and economic evaluation of the ketogenic diet versus care as usual in children and adolescents with intract...
-
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2qoeMDm via IFTTT
-
Relativistic hydrodynamics has been quite successful in explaining the collective behaviour of the QCD matter produced in high energy heavy-...
-
GE Healthcare has introduced Logiq S8 XDclear 2.0, an ultrasound system that... Read more on AuntMinnieEurope.com Related Reading: GE r...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου